Published online before print January 31, 2002, doi: 10.1161/01.ATV.0000012283.15789.67
© 2002 American Heart Association, Inc.
Vascular Biology |
Cerivastatin, an Inhibitor of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase, Inhibits Endothelial Cell Proliferation Induced by Angiogenic Factors In Vitro and Angiogenesis in In Vivo Models
From Laboratoire DIFEMA (L.V., C.S., F.M., J.-P.V., L.H.), UFR de Médecine et Pharmacie, Rouen, France; INSERM U553 (C.S.), Hôpital Saint Louis, Paris, France; Institut Gustave Roussy (P.O.), Villejuif, France; CNRS (Z.M.), IFR 2249, Villejuif, France; and Laboratoire de Biochimie and EMI 99-12 (J.S.), Hôtel-Dieu, Paris, France.
Reprint requests to Claudine Soria, Laboratoire DIFEMA, UFR de Médecine et Pharmacie, 22 Boulevard Gambetta, 76183 Rouen, France. E-mail claudine.soria{at}lrb.ap-hop-paris.fr
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Cerivastatin is an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase. It inhibits the biosynthesis of cholesterol and its precursors: farnesyl pyrophosphate and geranylgeranyl pyrophosphate (GGPP), which are involved in Ras and RhoA cell signaling, respectively. Statins induce greater protection against vascular risk than that expected by cholesterol reduction. Therefore, cerivastatin could protect plaque against rupture, an important cause of ischemic events. In this study, the effect of cerivastatin was tested on angiogenesis because it participates in plaque progression and plaque destabilization. Cerivastatin inhibits in vitro the microvascular endothelial cell proliferation induced by growth factors, whereas it has no effect on unstimulated cells. This growth arrest occurs at the G1/S phase and is related to the increase of the cyclin-dependent kinase inhibitor p21Waf1/Cip1. These effects are reversed by GGPP, suggesting that the inhibitory effect of cerivastatin is related to RhoA inactivation. This mechanism was confirmed by RhoA delocalization from cell membrane to cytoplasm and actin fiber depolymerization, which are also prevented by GGPP. It was also shown that RhoA-dependent inhibition of cell proliferation is mediated by the inhibition of focal adhesion kinase and Akt activations. Moreover, cerivastatin inhibits in vivo angiogenesis in matrigel and chick chorioallantoic membrane models. These results demonstrate the antiangiogenic activity of statins and suggest that it may contribute to their therapeutic benefits in the progression and acute manifestations of atherosclerosis.
Key Words: statins • angiogenesis inhibition • RhoA • vascular risk
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Neovascularization is an important process that is required for the progression of atherosclerosis.1,2 Increased vascularization is recognized as a major feature during plaque development.3 Its pathogenic role includes the supply of nutriments and oxygen and the accumulation of blood monocytes, which pass through the endothelium.4 In addition, angiogenesis could also be involved in destabilization of the plaque, leading to its rupture, which causes thrombosis and acute ischemic events.5 Moreover, the role of angiogenesis in atherosclerosis has been demonstrated by the histochemical examination of atherosclerotic plaque from autopsy specimens by Boyle et al,6 who showed a strong correlation between the severity of stenosis and plaque microvascular density. In addition, by examining plaque from patients with ischemic events, Jeziorska and Woolley7 reported that local hemorrhages derived from microvessels within the atherosclerotic plaque contribute to the acute complications of atherosclerosis by favoring plaque destabilization. McCarthy et al8 also reported that there were significantly more neovessels in plaques and fibrous caps in symptomatic compared with asymptomatic plaques.
Possible stimuli for plaque angiogenesis include local hypoxia and leukocyte-derived cytokines, such as vascular endothelial growth factor (VEGF), which has been detected in atherosclerotic plaque, or basic fibroblast growth factor (bFGF).9 Oncostatin M (OSM), secreted by activated monocytes and which is largely overexpressed in atherosclerotic plaque (especially in areas of aneurysm),10 has also recently been characterized as an angiogenic factor.11
Because the beneficial effect of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (these inhibitors are commonly named statins) in the prevention of vascular risk is extended beyond the lowering of plasma cholesterol levels,12 we were prompted to analyze the effect of a statin, cerivastatin, on endothelial cell proliferation and angiogenesis. Statins lead to a decreased synthesis of cholesterol as well as its precursors, which are isoprenoid products of mevalonate (MVA). The inhibition in the formation of these isoprenoids, farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP), could play an important role in altering the processing of signaling that requires lipophilic anchors to cell membranes. FPP is essential for membrane attachment and biological activity of small GTP-binding proteins from the Ras family,13 and GGPP is required for RhoA translocation to cell membranes.14
In the present study, we have shown that cerivastatin repressed in vitro the proliferative activity of angiogenic factors on microvascular endothelial cells (human microvascular endothelial cells [HMEC-1 cells]), which are representative of atherosclerotic plaque vascularization. Moreover, cerivastatin inhibits angiogenesis in vivo in the matrigel model in mice and in the chick chorioallantoic membrane (CAM).
These observations raised the important question of the mechanism by which cerivastatin induces its antiangiogenic effect. In the present study, we first examined the relative participation of RhoA and Ras inhibition on the antiangiogenic effect of cerivastatin. Second, we analyzed the effect of cerivastatin on cell cycle distribution and on the expression of the cyclin-dependent kinase inhibitor p21Waf1/Cip1, a negative regulator of cell cycle progression in late G1 phase. Third, to understand the molecular mechanism involved in this inhibition, we evaluated the modification of cell signaling induced by cerivastatin on bFGF-stimulated endothelial cells. As we reported that cerivastatin inhibits the formation of focal adhesion sites where focal adhesion kinase (FAK) is activated in the presence of Rho, we were prompted to particularly analyze the effect of cerivastatin on the cell-signaling cascade FAK/phosphatidylinositol (PI)-3-kinase (PI3K)/Akt. This was justified by the fact that phosphorylated Akt is markedly implicated in endothelial cell survival, proliferation, and angiogenesis.16–18
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Please see online data supplement (which can be accessed at http://www.atvb.ahajournals.org) for materials and methods concerning cytokines and cerivastatin, cell culture, cell proliferation assay, apoptosis analysis, adhesion assay, determination of cell cycle analysis, Western blot analysis, RNA isolation, reverse transcriptase–polymerase chain reaction assay, ELISA of p21Waf1/Cip, confocal microscopy analysis of RhoA and actin filaments, in vivo angiogenesis assays (matrigel model and chick CAM model), and statistical analysis.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Cerivastatin Inhibits Endothelial Cell Proliferation
From 10 to 25 ng/mL, cerivastatin induced a dose-dependant decrease in stimulated–endothelial cell proliferation in the presence of 2.5 ng/mL OSM, 25 ng/mL bFGF, or 20 ng/mL VEGF (Figure 1A and 1B). This phenomenon was associated with cell rounding. Higher concentrations were not tested because 50 ng/mL cerivastatin induced cell detachment from the surface of the well and, consequently, cell death, as assessed by the incorporation of trypan blue. In contrast, cerivastatin did not change the proliferation of unstimulated endothelial cells.
|
To analyze the contribution of isoprenoid synthesis inhibition by cerivastatin on its antiproliferative effect, we tested whether this inhibitory effect could be reversed by 100 µmol/L MVA, 10 µmol/L GGPP, or 10 µmol/L FPP. MVA and GGPP totally prevented the inhibitory effect of cerivastatin (10 and 25 ng/mL) on cytokine-induced endothelial cell proliferation (Figure 2A through 2D), whereas FPP did not prevent the inhibitory effect of cerivastatin (data not shown). These results suggest that cerivastatin induced an antiproliferative effect by the blockage of GGPP formation.
|
Cerivastatin Does Not Induce Endothelial Cell Apoptosis
Analysis of apoptosis by Hoechst 33342 staining was performed on bFGF-stimulated endothelial cells in the presence or absence of cerivastatin (10 and 25 ng/mL). Results of 4 individual experiments showed that a 24-hour incubation of endothelial cells with cerivastatin did not modify the apoptosis measured on adherent cells: the ratio of the number of apoptotic cells in cerivastatin-treated cells to the number of apoptotic cells in control cells was 1.07±0.06 and 0.97±0.04 for 10 ng/mL and 25 ng/mL cerivastatin, respectively. Moreover, PI incorporation was not observed, confirming the absence of cell permeability (data not shown).
Cerivastatin Induces Endothelial Cell Detachment
The effect of cerivastatin on endothelial cell detachment was expressed as the percentage of detached endothelial cells cultured in the presence of cerivastatin compared with that of control cells. Cerivastatin (25 ng/mL) induced a mild but significant increase in detached endothelial cells whether or not the cells were stimulated by bFGF (155±15% and 142±11% of control cells for cells stimulated with and without bFGF, respectively; P<0.001; n=3).
Cerivastatin Blocks G1/S Transition of Cell Cycle
Treatment with 10 or 25 ng/mL cerivastatin in the presence or absence of stimulation by OSM for 18 hours resulted in the accumulation of cells in the G0/G1 phase (online Figure IA; please see http://www.atvb.ahajournals.org), with a corresponding decrease in the number of cells in G2/M phase (online Figure IC). Cerivastatin treatment led to a significant reduction in OSM-stimulated endothelial cells in S-phase cells (online Figure IB). These results clearly demonstrate that cerivastatin controls cell cycle progression by an inhibition of the cell cycle at the G1/S phase. Moreover, the effect of cerivastatin on G1-phase cell cycle blockage was fully reversible by coincubation with MVA or GGPP but not with FPP (data not shown).
Cerivastatin Increases mRNA and Protein Expression of the Cyclin-Dependent Kinase Inhibitor p21Waf1/Cip1
In HMEC-1 cells, we assessed whether cerivastatin induced p21Waf1/Cip1, an inhibitor of the G1-phase cell cycle. As shown in Figure 3, cerivastatin (10 and 25 ng/mL) induced, in a dose-dependent manner, a marked increase in the level of p21Waf1/Cip1 protein and mRNA on unstimulated and bFGF-stimulated endothelial cells. To investigate whether RhoA or Ras inactivation accounted for the induction of p21Waf1/Cip1, we analyzed the effect of FPP and GGPP by ELISA. When HMEC-1 cells were treated with cerivastatin together with GGPP (10 µmol/L) or FPP (10 µmol/L), only GGPP reversed the stimulating effect of cerivastatin on p21Waf1/Cip1 expression (Table).
|
|
Cerivastatin Decreases the Phosphorylations of FAK (Phospho-Tyr397) and Akt (Phospho-Ser473)
We studied the effect of cerivastatin on FAK phosphorylation (Tyr397), which is mainly involved in the activation of the PI3K/Akt pathway. The incubation of bFGF-stimulated endothelial cells with cerivastatin induced a decrease in the phosphorylated FAK from 12 hours of incubation with 25 ng/mL cerivastatin. During the same period, a decrease in the phosphorylated Akt (Ser473) was induced by cerivastatin treatment and was maintained at 24 hours. These reductions are clearly related to a decrease in phosphorylation, because the total amount of FAK and Akt was not modified by cerivastatin treatment (Figure 4).
|
Cerivastatin-Induced Delocalization of RhoA From Cell Membrane and Actin Depolymerization Is Reversed by GGPP
As described in our previous study,15 in the absence of cerivastatin, RhoA was present at the membrane periphery and at the lamellipodia extensions of bFGF-treated cells. After a 24-hour treatment with 25 ng/mL cerivastatin, a rounding of the cells was observed with the disappearance of the lamellipodia. In addition, RhoA was translocated in the cytoplasm, mainly in the perinuclear region, and this effect led to the disruption of actin stress fibers.15 As shown in online Figure II (please see http://www.atvb.ahajournals.org), the effect of cerivastatin on RhoA delocalization and actin depolymerization was completely reversed by coincubation with GGPP (10 µmol/L). We verified that in the absence of the first antibody, no fluorescence was detected as control (data not shown).
Cerivastatin Inhibits bFGF-Induced Angiogenesis in Matrigel Model
In this model, subcutaneously injected matrigel rapidly solidified at body temperature, thereby trapping bFGF and cerivastatin. Mice that received matrigel containing 1 µg bFGF and 100 µg cerivastatin developed a limited number of discontinuous vessel spots around the matrigel plugs (data not shown). In contrast, mice that received matrigel containing only bFGF exhibited an abundant and continuous vascular network in the connective tissue around the matrigel plugs (data not shown). The vessel index, which was determined by using the Weidner method also showed a significant decrease in the bFGF- and cerivastatin-conditioned matrigel compared with the bFGF matrigel (15.66±0.71 versus 26.83±1.63, respectively; P<0.001). Without the induction of bFGF, vessel spots were very low, even with control, without any significant changes in the presence or absence of cerivastatin (6±0.50 versus 8.43±0.63 for cerivastatin-containing matrigel and mock matrigel, respectively).
Angiogenesis in the Chick CAM Is Inhibited by Cerivastatin
The antiangiogenic effect of cerivastatin in vivo was also evaluated in the chick CAM. Chick embryos were incubated with PBS (for control) or cerivastatin (50 ng) at day 6 of embryonic development with the use of an established shell-less culture technique. The effect of the additions on CAM angiogenesis was then analyzed after 4 days of incubation. Cerivastatin led to an efficient inhibition of angiogenesis in this assay compared with PBS-treated chick CAM. Indeed, the formation of microvessels was totally inhibited by cerivastatin treatment, whereas a great number of neovessels was formed in the control chick CAM. Furthermore, cerivastatin treatment did not destabilize the preexisting large vessels (Figure 5).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Statins have demonstrated their ability to lower hypercholesterolemia and to prevent the occurrence of arterial events (coronary and cerebral).12,19 However, recent evidence suggests that the beneficial effects of statins may extend beyond their effects on serum cholesterol levels.
Because statins, by inhibiting HMG-CoA reductase, prevent the synthesis of isoprenoid intermediates in the cholesterol biosynthetic pathway (FPP and GGPP), they may have pleiotropic effects on vascular wall cells. Moreover, FPP and GGPP are involved in membrane localization and cell signaling of the small GTP-binding proteins Ras and RhoA, respectively. Therefore, by preventing FPP and GGPP formation, statins could inhibit cellular events related to Ras or RhoA signaling.
Because angiogenesis plays a major role in the development and instability of atherosclerotic plaque, we sought to determine the effect of a statin, cerivastatin, in endothelial cell proliferation in vitro and angiogenesis in vivo. In our previous work, we have demonstrated that by inhibiting RhoA cell signaling, cerivastatin strongly inhibits endothelial cell locomotion and the matrix metalloproteinase-2 secretion involved in cell invasion and capillary tube formation. This effect was dependent on RhoA inhibition.15 However, cerivastatin does not modify the expression of urokinase by endothelial cells.
In the present study, we showed that cerivastatin inhibits, in a dose-dependent manner, the proliferation of microvascular endothelial cells when stimulated by angiogenic factors, such as bFGF, VEGF, and OSM, without an effect on apoptosis. Interestingly, cerivastatin did not modify the proliferation of endothelial cells in the absence of angiogenic factors. The antiproliferative effect of cerivastatin was fully reversible by coincubation with MVA or GGPP but not with FPP. This indicates that the inhibitory effect of cerivastatin on endothelial cell proliferation is mainly due to the inhibition of RhoA geranylation and not Ras farnesylation. Consistent with this observation, it was shown that cerivastatin induces actin depolymerization and RhoA delocalization from the cell membrane of bFGF-stimulated endothelial cells, which are also reversed by GGPP treatment.
The antiproliferative effect of cerivastatin was related to an arrest of the cell cycle in G1/S phase. This inhibition of cell proliferation is associated with an increase in the amount of p21Waf1/Cip1, a cyclin-dependent kinase inhibitor predominantly involved in G1/S transition, which is also reversed by GGPP. In the present study, we have also demonstrated that the increase in p21Waf1/Cip1 is caused by an increased synthesis and not by a decrease in proteasome-induced degradation. Indeed, cerivastatin also induced an increase in the p21Waf1/Cip1 mRNA. Our results are in agreement with the finding of Allal et al,20 who showed that the geranylgeranylation of RhoA is required for suppressing p21Waf1/Cip1 transcription. However, despite the absence of an effect of cerivastatin on basal endothelial cell proliferation, cerivastatin also induced an increase in p21Waf1/Cip1 on unstimulated endothelial cells. Therefore, it was assumed that the inhibitory effect of p21Waf1/Cip1 is efficient only on proliferative cells because of the sustained expression of D-type cyclins.21 This is in agreement with the observation that cerivastatin induced a potent inhibitory effect only on highly proliferative breast cancer cells.22,23
We also investigated the hypothesis that the increase in p21Waf1/Cip1 was not sufficient to explain the antiproliferative effect induced by cerivastatin. To address this point, we were prompted to analyze whether cerivastatin inhibits FAK (phospho-Tyr397) and Akt (phospho-Ser473) activations. FAK is targeted in focal adhesion complexes and is a downstream effector of RhoA.24 Moreover, the activation of FAK leads to its association with PI3K, which is required for Akt stimulation, which is strongly implicated in mediating diverse cellular biological functions of angiogenic growth factors, including cell survival, proliferation, and angiogenesis.25 This hypothesis is supported by our investigations showing that cerivastatin inhibits the bFGF-induced FAK and Akt phosphorylation, which is explained by the loss of focal adhesion sites and RhoA inhibition.
Whatever the mechanism of action, the antiangiogenic activity of cerivastatin was directly confirmed in 2 in vivo models (1) the formation of neovessels in bFGF-enriched matrigel introduced subcutaneously in the mice and (2) the chick CAM. These results also indicate that the effect of cerivastatin is observed in several types of microvascular endothelial cells and not only in microvascular cell lines. Moreover, the antiangiogenic effect of cerivastatin was also confirmed by using other endothelial cells from the microvasculature of bone marrow origin (human bone marrow endothelial cell; results are not shown).
Our results are in contrast with the recently published data of Kureishi et al,26 who reported that statins promote angiogenesis, a phenomenon attributed to Akt activation. This discrepancy with our findings could be attributed to the differences in our experimental models, inasmuch as Kureishi et al used endothelial cells without angiogenic factors. Under these conditions, we were unable to show any effect of cerivastatin. In fact, our results demonstrate that cerivastatin inhibits only the stimulatory effect of angiogenic factors on endothelial cells. This discrepancy could also be due to the difference of the endothelial cell origin, inasmuch as we used microcapillary endothelial cells, but these authors used human umbilical vascular endothelial cells or bovine aortic endothelial cells, which are representative of the macrovasculature. Moreover, the loss of adhesion emphasizes the involvement of Akt inactivation in cerivastatin-treated endothelial cells, as previously discussed. In addition, the present results are in agreement with the recent observation that Rho confines the expression of cyclin D1 to the mid-G1 phase of the cell cycle.27
In conclusion, we have demonstrated that cerivastatin inhibits the in vitro microcapillary endothelial cell proliferation induced by angiogenic growth factors and in vivo angiogenesis. This inhibitory effect is dependent on RhoA inhibition. Multiple mechanisms have been reported that can connect the inhibition of RhoA with the antiangiogenic activity of cerivastatin, including the increase in p21Waf1/Cip1 and the inhibition of the mitogenic signaling pathways downstream from FAK and PI3K/Akt. Whatever the mechanisms involved in the antiangiogenic activity of cerivastatin, the present findings suggest that it could contribute to the protective effect induced by cerivastatin on atherothrombosis by inhibiting the development of atherosclerosis and complications due to plaque rupture. This is in agreement with the observation that statins tend to inhibit the destabilization of the plaque responsible for its rupture.28,29
|
Acknowledgments |
|---|
L. Vincent is the recipient of a fellowship from le Groupement des Entreprises Françaises dans la Lutte contre le Cancer (GEFLUC). The authors thank GEFLUC, l’Association Régionale pour l’Enseignement et la Recherche Scientifique technologique (ARERS), la Région Haute Normandie, and the pharmaceutical company Bayer, especially Dr Bischoff, Dr Chartier, and Dr Barouki. The authors also thank Elisabeth Legrand for her technical support and Richard Medeiros for his valuable editorial assistance.
Received November 26, 2001; accepted December 19, 2001.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Battegay EJ. Angiogenesis. mechanistic insights, neovascular diseases, and therapeutic prospects. J Mol Med. 1995; 73: 333–346.[Medline] [Order article via Infotrieve]
2. O’Brien ER, Garvin MR, Dev R, Stewart DK, Hinohara T, Simpson JB, Schwartz SM. Angiogenesis in human coronary atherosclerotic plaques. Am J Pathol. 1994; 145: 883–894.[Abstract]
3. Zhang Y, Cliff WJ, Schoefl GI, Higgins G. Immunohistochemical study of intimal microvessels in coronary atherosclerosis. Am J Pathol. 1993; 143: 164–172.[Abstract]
4. Groszek E, Grundy SM. The possible role of the arterial microcirculation in the pathogenesis of atherosclerosis. J Chronic Dis. 1980; 33: 679–684.[CrossRef][Medline] [Order article via Infotrieve]
5.
Lee RT, Libby P. The instable atheroma. Arterioscler Thromb Vasc Biol. 1997; 17: 1859–1867.
6. Boyle JJ, Wilson B, Bicknell R, Harrower S, Weissberg PL, Fan TP. Expression of angiogenic factor thymidine phosphorylase and angiogenesis in human atherosclerosis. J Pathol. 2000; 192: 234–242.[CrossRef][Medline] [Order article via Infotrieve]
7. Jeziorska M, Woolley DE. Local neovascularization and cellular composition within vulnerable regions of atherosclerotic plaques of human carotid arteries. J Pathol. 1999; 188: 189–196.[CrossRef][Medline] [Order article via Infotrieve]
8. McCarthy MJ, Loftus IM, Thompson MM, Jones L, London NJ, Bell PR, Naylor AR. Angiogenesis and the atherosclerotic carotid plaque: an association between symptomatology and plaque morphology. J Vasc Surg. 1999; 30: 261–268.[CrossRef][Medline] [Order article via Infotrieve]
9. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992; 359: 843–845.[CrossRef][Medline] [Order article via Infotrieve]
10. Modur V, Feldhaus MJ, Weyrich AS, Jicha DL, Prescott SM, Zimmerman GA, McIntyre TM. Oncostatin M is a proinflammatory mediator. J Clin Invest. 1997; 100: 158–168.[Medline] [Order article via Infotrieve]
11.
Vasse M, Pourtau J, Trochon V, Muraine M, Vannier JP, Lu H, Soria J, Soria C. Oncostatin M induces angiogenesis in vitro and in vivo. Arterioscler Thromb Vasc Biol. 1999; 19: 1835–1842.
12. Dangas G, Smith DA, Unger AH, Shao JH, Meraj P, Fier C, Cohen AM, Fallon JT, Badimon JJ, Ambrose JA. Pravastatin: an antithrombotic effect independent of the cholesterol-lowering effect. Thromb Haemost. 2000; 83: 688–692.[Medline] [Order article via Infotrieve]
13. Elson CE, Peffley DM, Hentosh P, Mo H. Isoprenoid-mediated inhibition of mevalonate synthesis: potential application to cancer. Proc Soc Exp Biol Med. 1999; 221: 294–311.[CrossRef][Medline] [Order article via Infotrieve]
14. Yoshida Y, Kawata M, Katayama M, Horiuchi H, Kita Y, Takai Y. A geranylgeranyltransferase for rhoA p21 distinct from the farnesyltransferase for Ras p21S. Biochem Biophys Res Commun. 1991; 175: 720–728.[CrossRef][Medline] [Order article via Infotrieve]
15. Vincent L, Chen W, Hong L, Mirshahi F, Mishal Z, Mirshahi-Khorassani T, Vannier JP, Soria J, Soria C. Inhibition of endothelial cell migration by cerivastatin, an HMG-CoA reductase inhibitor: contribution to its anti-angiogenic effect. FEBS Lett. 2001; 495: 159–166.[CrossRef][Medline] [Order article via Infotrieve]
16.
Zachary I, Gliki G. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc Res. 2001; 49: 568–581.
17.
Dimmeler S, Zeiher AM. Akt takes center stage in angiogenesis signaling. Circ Res. 2000; 86: 4–5.
18. Ilan N, Mahooti S, Madri JA. Distinct signal transduction pathways are utilized during the tube formation and survival phases of in vitro angiogenesis. J Cell Sci. 1998; 111: 3621–3631.[Medline] [Order article via Infotrieve]
19. Vaughan CJ, Murphy MB, Buchley BM. Statins do more that just lower cholesterol. Lancet. 1996; 348: 1079–1082.[CrossRef][Medline] [Order article via Infotrieve]
20.
Allal C, Favre G, Couderc B, Salicio S, Sixou S, Hamilton AD, Sebti SM, Lajoie-Mazenc I, Pradines A. RhoA prenylation is required for promotion of cell growth and transformation, cytoskeleton organization, but not for induction of SRE transcription. J Biol Chem. 2000; 275: 31001–31008.
21. Ekholm SV, Reed SI. Regulation of G(1) cyclin-dependent kinases in the mammalian cell cycle. Cur Opin Cell Biol. 2000; 12: 676–684.[CrossRef][Medline] [Order article via Infotrieve]
22.
Denoyelle C, Vasse M, Körner M, Mishal Z, Ganne F, Vannier JP, Soria J, Soria C. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis. 2001; 22: 1139–1148.
23. Feleszko W, Mlynarczuk I, Nowis D. In vitro antitumor activity of cerivastatin, a novel and potent HMG-CoA reductase inhibitor. FEBS Lett. 2001; 503: 219–220.[CrossRef][Medline] [Order article via Infotrieve]
24. Parsons JT. Integrin-mediated signalling: regulation by protein tyrosine kinases and small GTP-binding proteins. Curr Opin Cell Biol. 1996; 8: 146–152.[CrossRef][Medline] [Order article via Infotrieve]
25.
Zubilewicz A, Hecquet C, Jeanny J, Soubrane G, Courtois Y, Mascarelli F. Proliferation of CECs requires dual signaling through both MAPK/ERK and PI 3-K/Akt pathways. Invest Ophthalmol Vis Sci. 2001; 42: 488–496.
26. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, Sessa WC, Walsh K. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med. 2000; 6: 1004–1010.[CrossRef][Medline] [Order article via Infotrieve]
27. Coleman ML, Marshall CJ. A family outing: small GTPases cyclin’ through G1. Nat Cell Biol. 2001; 3: E250–E251.[CrossRef][Medline] [Order article via Infotrieve]
28. Dupuis J. Mechanisms of acute coronary syndromes and the potential role of statins. Atherosclerosis. 2001; 2 (suppl): 9–14.[CrossRef][Medline] [Order article via Infotrieve]
29. Weissberg P. Mechanisms modifying atherosclerotic disease: from lipids to vascular biology. Atherosclerosis. 1999; 147: (suppl)1: S3–S10.[CrossRef][Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  M. Rodriguez-Yanez, J. Agulla, R. Rodriguez-Gonzalez, T. Sobrino, and J. Castillo Review: Statins and stroke Therapeutic Advances in Cardiovascular Disease, June 1, 2008; 2(3): 157 - 166. [Abstract] [PDF]
|
|
|
|
 |
|
 F. D. Kolodgie, J. Narula, C. Yuan, A. V. Finn, H. K. Gold, and R. Virmani Reply J. Am. Coll. Cardiol., October 9, 2007; 50(15): 1521 - 1521. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Oktem, I. Esinler, D. Eroglu, N. Haberal, N. Bayraktar, and H. B. Zeyneloglu High-dose atorvastatin causes regression of endometriotic implants: a rat model Hum. Reprod., May 1, 2007; 22(5): 1474 - 1480. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X.-Y. Zhu, E. Daghini, A. R. Chade, C. Napoli, E. L. Ritman, A. Lerman, and L. O. Lerman Simvastatin Prevents Coronary Microvascular Remodeling in Renovascular Hypertensive Pigs J. Am. Soc. Nephrol., April 1, 2007; 18(4): 1209 - 1217. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Saijonmaa, T. Nyman, and F. Fyhrquist Atorvastatin inhibits angiotensin-converting enzyme induction in differentiating human macrophages Am J Physiol Heart Circ Physiol, April 1, 2007; 292(4): H1917 - H1921. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Xu, L. Zeng, H. Peng, S. Chen, J. Jones, T.-L. Chew, M. M. Sadeghi, Y. S. Kanwar, and F. R. Danesh HMG-CoA reductase inhibitor simvastatin mitigates VEGF-induced "inside-out" signaling to extracellular matrix by preventing RhoA activation Am J Physiol Renal Physiol, November 1, 2006; 291(5): F995 - F1004. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Yao, R.-H. Zhou, M. Petreaca, L. Zheng, J. Shyy, and M. Martins-Green Activation of sterol regulatory element-binding proteins (SREBPs) is critical in IL-8-induced angiogenesis J. Leukoc. Biol., September 1, 2006; 80(3): 608 - 620. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. J. Zambarakji, T. Nakazawa, E. Connolly, A. M. Lane, S. Mallemadugula, M. Kaplan, N. Michaud, A. Hafezi-Moghadam, E. S. Gragoudas, and J. W. Miller Dose-dependent effect of pitavastatin on VEGF and angiogenesis in a mouse model of choroidal neovascularization. Invest. Ophthalmol. Vis. Sci., June 1, 2006; 47(6): 2623 - 2631. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T.-S. Li, M. Takahashi, R. Suzuki, T. Kobayashi, H. Ito, A. Mikamo, and K. Hamano Pravastatin Improves Remodeling and Cardiac Function After Myocardial Infarction by an Antiinflammatory Mechanism Rather than by the Induction of Angiogenesis Ann. Thorac. Surg., June 1, 2006; 81(6): 2217 - 2225. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Hindler, C. S. Cleeland, E. Rivera, and C. D. Collard The Role of Statins in Cancer Therapy. Oncologist, January 1, 2006; 11(3): 306 - 315. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Epstein, E. Stabile, T. Kinnaird, C. W. Lee, L. Clavijo, and M. S. Burnett Janus Phenomenon: The Interrelated Tradeoffs Inherent in Therapies Designed to Enhance Collateral Formation and Those Designed to Inhibit Atherogenesis Circulation, June 15, 2004; 109(23): 2826 - 2831. [Full Text] [PDF]
|
|
|
|
|
|
O. Saijonmaa, T. Nyman, P. Stewen, and F. Fyhrquist Atorvastatin completely inhibits VEGF-induced ACE upregulation in human endothelial cells Am J Physiol Heart Circ Physiol, June 1, 2004; 286(6): H2096 - H2102. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. K. Liao Statin Therapy: Having the Good Without the Bad Hypertension, June 1, 2004; 43(6): 1171 - 1172. [Full Text] [PDF]
|
|
|
|
|
|
U. Schonbeck and P. Libby Inflammation, Immunity, and HMG-CoA Reductase Inhibitors: Statins as Antiinflammatory Agents? Circulation, June 1, 2004; 109(21_suppl_1): II-18 - II-26. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. R. DANESH and Y. S. KANWAR Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy FASEB J, May 1, 2004; 18(7): 805 - 815. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Zbinden, N Brunner, K Wustmann, M Billinger, B Meier, and C Seiler Effect of statin treatment on coronary collateral flow in patients with coronary artery disease Heart, April 1, 2004; 90(4): 448 - 449. [Full Text] [PDF]
|
|
|
|
|
|
C. R. Wolfram Kuhlmann, C. Gast, F. Li, M. Schafer, H. Tillmanns, B. Waldecker, and J. Wiecha Cerivastatin Activates Endothelial Calcium-Activated Potassium Channels and Thereby Modulates Endothelial Nitric Oxide Production and Cell Proliferation J. Am. Soc. Nephrol., April 1, 2004; 15(4): 868 - 875. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Wang, M. G. Hasham, I. Isordia-Salas, A. Y. Tsygankov, R. W. Colman, and Y.-L. Guo Regulation of Cardiovascular Signaling by Kinins and Products of Similar Converting Enzyme Systems: Upregulation of Cdc2 and cyclin A during apoptosis of endothelial cells induced by cleaved high-molecular-weight kininogen Am J Physiol Heart Circ Physiol, June 1, 2003; 284(6): H1917 - H1923. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Wolfrum, K. S. Jensen, and J. K. Liao Endothelium-Dependent Effects of Statins Arterioscler. Thromb. Vasc. Biol., May 1, 2003; 23(5): 729 - 736. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. P. van Nieuw Amerongen, P. Koolwijk, A. Versteilen, and V. W.M. van Hinsbergh Involvement of RhoA/Rho Kinase Signaling in VEGF-Induced Endothelial Cell Migration and Angiogenesis In Vitro Arterioscler. Thromb. Vasc. Biol., February 1, 2003; 23(2): 211 - 217. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Shiojima and K. Walsh Role of Akt Signaling in Vascular Homeostasis and Angiogenesis Circ. Res., June 28, 2002; 90(12): 1243 - 1250. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||